AML 0.00% 11.5¢ aeon metals limited.

why the stock is a buy

  1. 5,819 Posts.
    lightbulb Created with Sketch. 102
    Article from Dow Jones Business Wire

    ( BW)(NJ-MERCK)(MRK) Merck Licenses Amrad Technology to Develop New Asthma Drugs

    Business Editors/Health/Medical Writers

    WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--June 23, 2003--Merck & Co., Inc. and Amrad Corporation Limited (ASX:AML) today announced an exclusive licensing and multi-year research collaboration agreement between Merck Sharp & Dohme (Australia) Pty. Limited, the Australian subsidiary of Merck, and Amrad. Based on the results of the collaboration, Merck will seek to develop drugs with therapeutic potential in areas such as asthma, other types of respiratory disease, and oncology.
    Under the agreement with Merck, Amrad will receive an upfront payment of $5 million. Total potential payments to Amrad by Merck based on the successful development of a human health product for all indications would amount to a total of $112 million. Amrad would also receive royalties for commercialized products. Amrad and Merck will work together to investigate drug candidates, with Merck being solely responsible for all clinical development and marketing.
    Dr. Peter S. Kim, president of Merck Research Laboratories, cites this agreement as a significant entry by Merck into the biologics arena and consistent with Merck's continuing emphasis on external partnerships to supplement its world-class research capabilities.
    "We are delighted to broaden our longstanding relationship with Amrad. This agreement will help to accelerate our development efforts in the biologics arena where we already have substantial technical and scientific capabilities," Dr. Kim said.
    Amrad Managing Director, Dr Sandra Webb, said this deal demonstrates the value of Amrad's drug discovery program and intellectual property. It confirms the excellence of the basic research conducted at the Cooperative Research Center for Cellular Growth Factors (CRC-CGF) and Melbourne's Walter and Eliza Hall Institute, and Amrad's ability to extend and commercialize that research.
    "We are delighted to enter this collaboration with Merck as its strong skills in development and marketing make Merck an ideal partner. More importantly, we believe that by collaborating with Merck we can accelerate the pre-clinical investigation and clinical development of drugs based on this exciting target," Dr. Webb said.

    About Merck

    Merck & Co., Inc. is a global, research-driven pharmaceutical products and services company. Merck discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through joint ventures.

    My reasons
    There is a great chance for Merck to to a stake in Amrad for its discoveries

    Merck is basically funding the process to enhance the research

    The stock in the short term may possible move to over $1.00 on its relationship with Merck

    Read the disclaimer below
 
watchlist Created with Sketch. Add AML (ASX) to my watchlist
(20min delay)
Last
11.5¢
Change
0.000(0.00%)
Mkt cap ! $77.51M
Open High Low Value Volume
11.0¢ 11.5¢ 11.0¢ $3.778K 34K

Buyers (Bids)

No. Vol. Price($)
1 2600 11.0¢
 

Sellers (Offers)

Price($) Vol. No.
11.5¢ 6068 2
View Market Depth
Last trade - 16.10pm 22/11/2019 (20 minute delay) ?
(live)
Last
11.0¢
  Change
0.000 ( 4.35 %)
Open High Low Volume
10.5¢ 11.0¢ 10.5¢ 21506
Last updated 15.45pm 22/11/2019 (live) ?
AML (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.